Management of dyspepsia and peptic ulcer disease

Alternative Therapies in Health and Medicine

Volumn 11, Issue 5, 2005, Pages

  Ryan, Susan W ^a,b,c  

^a ROSE MEDICAL CENTER   (United States)

^b 7 Mile Emergency Medical Clinic   (United States)

^c INNOVISION COMMUNICATIONS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ACETYLSALICYLIC ACID; ALENDRONIC ACID; ALUMINUM MAGNESIUM HYDROXIDE; AMOXICILLIN; ASCORBIC ACID; BICARBONATE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM CARBONATE; CARNOSINE; CELECOXIB; CLARITHROMYCIN; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; IBUPROFEN; METFORMIN; METRONIDAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; RANITIDINE BISMUTH CITRATE; RISEDRONIC ACID; ROFECOXIB; TETRACYCLINE; VALDECOXIB; ZINC;

DIGESTION; DYSPEPSIA; ENDOSCOPIC BIOPSY; ENZYME LINKED IMMUNOSORBENT ASSAY; HELICOBACTER PYLORI; HUMAN; LIFESTYLE; MORBIDITY; MORTALITY; PEPTIC ULCER; PREVALENCE; REVIEW; RISK FACTOR;

ANTACIDS; ANTI-BACTERIAL AGENTS; ANTI-ULCER AGENTS; DYSPEPSIA; HELICOBACTER INFECTIONS; HUMANS; PEPTIC ULCER; PHYTOTHERAPY;

EID: 24744443534     PISSN: 10786791     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. Tuteja A. Overlap of functional dyspepsia and irritable bowel syndrome in a community sample. Findings presented at the 68th Annual Scientific Meeting of the American College of Gastroenterology. Baltimore, Md: Oct 13, 2003.
2. Bazaldua OV, Scheider FD. Evaluation and management of dyspepsia. Am Fam Physician. 1999;60:1773-1784, 1787-1788.
3. Fennerty MB. NSAID-related gastrointestinal injury. Evidence-based approach to a preventable complication. Postgrad Med. 2001;110:87-88, 91-94.
4. Marotta RB, Floch MH. Diet and nutrition in ulcer disease. Med Clin North Am. 1991;75:967-969.
5. Aldoori WH, Giovannucci EL, Stampfer MJ, et al. Prospective study of diet and the risk of duodenal ulcer in men. Am J Epidemiol. 1997;145:42-50.
6. Aldoori WH, Giovannucci EL, Stampfer MJ, et al. A prospective study of alcohol, smoking, caffeine and the risk of duodenal ulcer in men. Epidemiology. 1997;8:420-424.
7. Drossman DA, Corazziari E, Talley NJ, Thompson WG, Whitehead WE, eds. Rome II: The Functional Gastrointestinal Disorders: Diagnosis, Pathophysiology, and Treatment: A Multinational Consensus. 2nd ed. McLean, Va: Degnon Associates; 2000.
8. Scheiman JM. NSAIDs, gastrointestinal injury, and cytoprotection. Gastroenterol Clin North Am. 1996;25:279-98.
9. Breuer T, Goodman KJ, Malaty HM, Sudhop T, Graham DY. How do clinicians practicing in the US manage Helicobacter pylori-related gastrointestinal diseases? A comparison of primary care and specialist physicians. Am J Gastronenterol. 1998;114:579-581.
10. Graham DY, Malaty HM, Evans DG, et al. Epidemiology of Helicobacter pylori in an asymptomatic population in the United States. Effect of age, race, and socioeconomic status. Gastroenterology. 1991;100:1495-1501.
11. Blum AL, Talley NJ, O'Morain C, et al. Lack of effect of treating Hdicobacter pylori infection in patients with nonulcer dyspepsia. N Engl J Med. 1998;339:1875-1881.
12. American Gastroenterological Association medical position statement: evaluation of dyspepsia. Gastroenterology. 1998;114:579-581.
13. Meurer LN, Bower DJ. Management of Helicobacter pylori infection. Am Fam Physician. 2002;65:1327-1336.
14. Snyder JD, Veldhayzen Van Zanten S. Novel diagnostic tests to detect Helicobacter pylori infection: a pediatric perspective. Can J Gastroenterol. 1999;13:585-589.
15. Feldman M, Cryer B, Lee E, Peterson WL. Role of seroconversion in confirming cure of Helicobacter pylori infection. JAMA. 1998;280:363-365.
16. Howden CW, Hunt RH. Guidelines for the management of Helicobacter pylori infection. Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. Am J Gastroenterol. 1998;93:2330-2338.
17. Trevisani L, Sartori S, Ruina M, et al. Helicobacter pylori stool antigen test: clinical evaluation and cost analysis of a new enzyme immunoassay. Dig Dis Sci. 1999;44:2303-2306.
18. Forbes GM, Glaser ME, Cullen DJ, et al. Duodental ulcer treated with Helicobacter pylori eradication: seven-year followup. Lancet. 1994;343:258-260.
19. Laine L, Hopkins RJ, Girardi LS. Has the impact of Helicobacter pylori therapy on ulcer recurrence in the United States been overstated? A meta-analysis of rigorously designed trials. Am J Gastroenterol. 1998;93:1409-1415.
20. Graham DY, Lew GM, Klein PD, et al. Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodental ulcer. Ann Intern Med. 1992;116:705-708.
21. Laine L, Schoenfield P, Fennerty MA. Therapy for Helicobacter pylori in patients with nonulcer dyspepsia. A meta-analysis of randomized, controlled trials. Ann Intern Med. 2001;134:361-369.
22. Moayyedi P, Soo S, Deeks J, et al. Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Database Syst Rev. 2001;1CD002096.
23. Moayyedi P, Soo S, Deeks J, et al. Pharmacological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev. 2004;CD001960.
24. Moayyedi P, Soo S, Deeks J, et al. Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Database Syst Rev. 2005;CD002096.
25. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection - the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther. 2002;16:167-180.
26. van der Hulst RW, Keller JJ, Rauws EA, Tytgat GN. Treatment of Helicobacter pylori infection: a review of the world literature. Helicobacter. 1996;1:6-19.
27. Walsh JH, Peterson WL. The treatment of Helicobacter pylori infection in the management of peptic ulcer disease. N Engl J Med. 1995;333:984-991.
28. Katelaris PH, Forbes GM, Talley NJ, Crotty B. A randomized comparison of quadruple and triple therapies for Helicobacter pylori eradication: The QUADRATE Study. Gastroenterology. 2002;123:1763-1769.
29. Murray MT. The Healing Power of Herbs: The Enlightened Person's Guide to the Wonders of Medicinal Plants. 2nd ed. Roseville, Calif: Prima Publishing. 1995:228-235.
30. Malfertheiner P, Leodolter A, Peitz U. Cure of Helicobacter pylori-associated ulcer disease through eradication. Baillieres Best Pract Res Clin Gastroenterol. 2000;14:119-132.
31. Vakil N, Lanza F, Schwartz H, Barth J. Seven-day therapy for Helicobacter pylori in the United States. Aliment Pharmacol Ther. 2004;20:99-107.
32. McNulty CA, Dent J, Wise R. Susceptibility of clinical isolates of Campylobacter pylori to 11 antimicrobial agents. Antimicrob Agents Chemother. 1985;28:838-838.
33. Gorbach SL. Bismuth therapy in gastrointestinal diseases. Gastroenterology. 1990;99:863-875.
34. Mitscher LA, Park YH, Clark D, Beal JL. Antimicrobial agents from higher plants. Antimicrobial isoflavanoids and related substances from Glycyrrhiza glabra L. var. typica. J Nat Prod. 1980;43:259-269.
35. Morgan AG, Pacsoo C, McAdam WA. Maintenance therapy: a two-year comparison between Caved-S and cimetidine treatment in the prevention of symptomatic gastric ulcer recurrence. Gut. 1985;26:599-602.
36. Bennett A, Clark-Wibberley T, Stamford IF, Wright JE. Aspirin-induced gastric mucosal damage in rats: cimetidine and deglycyrrhizinated liquorice together give greater protection than low doses of either drug alone. J Pharm Pharmacol. 1980;32:151.
37. Borrelli F, Izzo AA. The plant kingdom as a source of anti-ulcer remedies. Phytother Res. 2000;14:581-591.
38. Kassir ZA. Endoscopic controlled trial of four drug regimnes in the treatement of chronic duodenal ulceration. Ir Med J. 1985;78:153-156.
39. Sandstead HH. Understanding zinc: recent observations and interpretations. J Lab Clin Med. 1994;124:322-327.
40. Liszewski RF. The effect of zinc on wound healing: a collective review. J Am Osteopath Assoc. 1981;81:104-106.
41. Kashimura H, Suzuki K, Hassan M, et al. Polaprezinc, a mucosal protective agent, in combination with lansoprazole, amoxicillin, and clarithromycin increases the cure rate of Helicobacter pylori infection. Aliment Pharmacol Ther. 1999;13:483-487.
42. Nishiwaki H, Kato S, Sugamoto S, et al. Ulcerogenic and healing impairing actions of monochloramine in rat stomachs: effects of zinc L-carnosine, polaprezinc. J Physiol Pharmacol. 1999;50:183-195.
43. Handa O, Yoshida N, Tanaka Y, etal. Inhibitory effect of polaprezinc on the inflammatory response to Helicobacter pylori. Can J Gastroenterol. 2002;16:785-789.
44. Fuji Y, Matsura T, Kai M, Kawasaki H, Yamada K. Protection by polaprezinc, an anti-ulcer drug, against indomethacin-induced apoptosis in rat gastric mucosal cells. Jpn J Pharmacol. 2000;84:63-70.
45. Kim DS, Lee MS, Kim YS, et al. Effect modification by vitamin C on the relation between gastric cancer and Helicobacter pylori. Eur J Epidemiol. 2005;20:67-71.
46. Konturek PC, Kania J, Gessner U, et al. Effect of vitamin C-releasing acetylsalicylic acid on gastric mucosal damage before and after Helicobacter pylori eradication therapy. Eur J Pharmacol. 2004;506:169-177.
47. Jaarin K, Renuvathani M, Nafeeza MI, Gapor MT. Comparative effect of palm vitamin E and ranitidine on the healing of ethanol-induced gastric lesions in rats. Int J Exp Pathol. 1999;80:259-263.
48. Jaarin K, Gapor MT, Nafeeza MI, Fauzee AM. Effect of various doses of palm vitamin E and tocopherol on aspirin-induced gastric lesions in rats. Int J Exp Pathol. 2002;83:295-302.
49. Jaarin K, Gapor MT, Fauzee AM. Vitamin E and its effect on aspirin induce gastric lesion in rats. Asia Pac J Clin Nutr. 2004;13:S170.
50. Elta GH, Behler EM, Colturi TJ. Comparison of coffee intake and coffee-induced symptoms in patients with duodenal ulcer, nonulcer dyspepsia, and normal controls. Am J Gastroenterol. 1990;85:1339-1342.
51. Dinoso VP. The effect of alcohol, tobacco, and coffee on the gastric mucosa. Gastroenterol Clin Biol. 1985;9(pt 2):84-87.
52. Brenner H, Berg G, Lappus N, Kliebsch U, Bode G, Boeing H. Alcohol consumption and Helicobacter pylori infection: results from the German National Health and Nutrition Survey. Epidemiology. 1999;10:214-218.